About the Author\nBharat Jasani, BSc, PhD, MBChB, FRCPath. Qualifying with honours in Biochemistry (University of Glasgow,1965-1969), PhD in Experimental Pathology and MBChB (honours distinction in Pathology) (University of Birmingham, 1970-1973), Dr Jasani initiated his clinical and research training in Histopathology, at Wales National School of Medicine in 1977, achieving MRCPath (1989), FRCPath (1997), and a Specialist Consultant’s status in Histopathology (Immunohistochemistry) (1993); and Personal Chair in Oncological Pathology (2003). Following his retirement as the Head of Histopathology and Academic Pathology (2003-2011), he continued as Professor of Pathology, Institute of Cancer & Genetics, Cardiff University & Associate Postgraduate Dean for Academic Medicine in Wales (2011-2015). He was then appointed as the Chair of Biomedical Sciences, Nazarbayev University School of Medicine. Astana, Kazakhstan, with Adjunct Professorship in Pathology, University of Pittsburgh School of Medicine, Pittsburg, USA (2015-2016). In 2016 he took up his current position as the Director of Pathology, Targos Molecular Pathology GmbH, Kassel, Germany, which was acquired by Discovery Life Sciences in 2021. Over the past 40 years Dr Jasani has devoted himself to advancing cancer pathology based on the use of cancer biomarkers. As the Head of Molecular Diagnostic Unit, University Hospital of Wales (1982-2003), he led the development and establishment of diagnostic immunocytochemistry & molecular pathology services in Cardiff and Wales. He also promoted quality assurance and standardization of cancer biomarker analyses as Breast Cancer Module Leader of UKNEQAS of IHC/ISH, and UK’s lead representative on International Working Group on Standardization of Breast Cancer Biomarking, and the United States Sub-Committee on Quality Assurance for Immunocytochemistry. As Principal Investigator and Co-investigator of several translational research projects on development of predictive biomarkers for colorectal and breast cancer, he has also been invited to act as a Consultant and Key Opinion Leader to several leading biotech and pharmaceutical companies. He is an author of a book, over 50 chapters and reviews and more than 200 peer reviewed research publications.\nRalf Huss, M.D., Ph.D. Ralf Huss holds an M.D. degree from the University of Erlangen-Nuremberg, and Ph.D. degree from the Ludwig-Maximilians-University Munich. Following internships and residencies in Medicine, Immunology and Transplantation Biology at the Memorial-Sloan-Kettering Cancer Center in NYC, the University Hospital in Zurich, Switzerland and the Fred Hutchinson Cancer Research Center in Seattle, WA, Dr. Huss was appointed senior resident at the Institute of Immunology in Essen, Germany in 1994, before he moved to the Ludwig-Maximilians-University in Munich to complete his training in anatomical, surgical and molecular pathology. In 2005 he was appointed Global Head of Pathology and Tissue Biomarker at the Pharmaceutical company Roche (Switzerland and Germany). After pioneering the integration of image analysis and computational pathology into the clinical histopathology workflow together with the Nobel Laureate Gerd Binnig at Definies / AstraZeneca, in 2020, Dr. Huss returned to academia and is currently Professor and Deputy Director at the Institute of Pathology and Molecular Diagnostics and at the Institute for Digital Medicine, University Hospital Augsburg, Germany. Professor Huss has published more than 150 scientific papers and 4 books in the fields of cell therapy, tissue phenomics and artificial intelligence in pathology. Dr. Huss holds several patents and has served as a Board member and / or consultant to a number of private and public corporations.\nClive Roy Taylor, M.D., D. Phil., MRCP (Ir), FRCPath. Clive Taylor holds M.A. and M.D. degrees from the University of Cambridge, and M.A. and D. Phil degrees from the University of Oxford. Following internships in Medicine an

Precision Cancer Medicine: Role of the Pathologist

Medical Books

Taylor, Clive R.

Jasani, Bharat

Huss, Ralf

Medicine

Springer

This textbook is a comprehensive overview of the development of cell-based biopharmaceuticals. Beginning with the underlying biology of stem cell and cell-based products, it traces the long and complex journey from preclinical concept to initiation of a pivotal clinical trial and the potential business model behind it.
The book also takes into consideration the different regulatory landscapes and their continuous evolution in Europe, North America and other parts of the world. The authors describe a path to manufacture a clinical grade therapeutic that passes all necessary quality measures as a robust and marketable product including an outlook on next generation products and innovative strategies.
This reference book is a must-have guide for any professional already active in biopharmaceuticals and anyone interested in getting involved in a scientific, medical or business capacity.

ADVANCES IN PHARMACEUTICAL CELL THERAPY: PRINCIPLES OF CELL-BASED BIOPHARMACEUTICALS

Science & Math

Guenther, Christine

Hauser, Andrea Josefine

Biological Sciences

World Scientific Pub Co Inc

In the age of digitization our society is transformed into a new state. In particular, machine intelligence dramatically elevates our capability to create and digest information. Naturally, healthcare is also impacted by this trend and will even be more transformed into a informatic driven discipline in the future. In the most important area of histo-pathology, the interpretation of tissue slices from cancer patients, informatics will have an early and huge impact on treatment decisions and probably will act as the leading discipline for this transformation in medicine. Tissue Phenomics provides a comprehensive methodology aiming at the discovery of the most accurate tissue-based decision support algorithm by close integration of assay development, image analysis and bioinformatics, and optimization feedback loops. In this book the methodology of Tissue Phenomics and its benefits and wealth’s are described. The different components of Tissue Phenomics are explained in the different chapters. In the chapters 2 to 4 of this book different authors describe various approaches on how to convert the wealth of tissue slide pixel data into mineable information using knowledge-based and data-driven image analysis methods. Subsequently, the datafication of images and the bioinformatics part plays a crucial role in generating prognostic and predictive models for disease progression. The integration of other data sources such as genomics, radiomics and patient related information is also important and is described as well. As discussed in chapters 5 and 6, these models may classify patients in distinct groups such as those responding to a given therapy. Since Tissue Phenomics provides a huge set of potentially prognostic features (phenes), one focus of both chapters is robust feature selection methods by advanced Monte-Carlo cross validation algorithms. In chapter 7 we discuss multiple application examples of Tissue Phenomics in academic and commercial settings and its tremendous impact to advances in biomedical sciences. Building on the successes in research, chapters 8 and 9 discuss applications in clinical environments and provide a flavor to the future envision in chapter 10, where tissue datafication and subsequent patient profiling is part of every routine examination, with the goal to best match patients with the most successful therapy, as predicted by tissue phenes.

Tissue Phenomics: Profiling Cancer Patients for Treatment Decisions: Profiling Cancer Patients for Treatment Decisions

Schmidt, Günter

Binnig, Gerd

Jenny Stanford Publishing

Digital Medicine: Bringing Digital Solutions to Medical Practice

See the best price to sell, buy, or rent books by Huss, Ralf. BookScouter helps to compare book prices from 25+ online bookstores and 30+ buyback vendors with a single search.

Books by Huss, Ralf